{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T11:57:01Z","timestamp":1783511821997,"version":"3.55.0"},"reference-count":56,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R00DA042127"],"award-info":[{"award-number":["R00DA042127"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA056407"],"award-info":[{"award-number":["R01DA056407"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients with opioid use disorder (OUD) tend to get assigned to one of 3 medications based on the treatment program to which the patient presents (e.g., opioid treatment programs tend to treat patients with methadone, while office-based practices tend to prescribe buprenorphine). It is possible that optimally matching patients with treatment type would reduce the risk of return to regular opioid use (RROU). We analyzed data from 3 comparative effectiveness trials from the US National Institute on Drug Abuse Clinical Trials Network (CTN0027, 2006\u20132010; CTN0030, 2006\u20132009; and CTN0051 2014\u20132017), in which patients with OUD (n\u00a0= 1,459) were assigned to treatment with either injection extended-release naltrexone (XR-NTX), sublingual buprenorphine-naloxone (BUP-NX), or oral methadone. We learned an individualized rule by which to assign medication type such that risk of RROU during 12 weeks of treatment would be minimized, and then estimated the amount by which RROU risk could be reduced if the rule were applied. Applying our estimated treatment rule would reduce risk of RROU compared with treating everyone with methadone (relative risk (RR)\u00a0= 0.79, 95% confidence interval (CI): 0.60, 0.97) or treating everyone with XR-NTX (RR\u00a0= 0.71, 95% CI: 0.47, 0.96). Applying the estimated treatment rule would have resulted in a similar risk of RROU to that of with treating everyone with BUP-NX (RR\u00a0= 0.92, 95% CI: 0.73, 1.11).<\/jats:p>","DOI":"10.1093\/aje\/kwac217","type":"journal-article","created":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T02:31:20Z","timestamp":1671762680000},"page":"748-756","source":"Crossref","is-referenced-by-count":8,"title":["Optimally Choosing Medication Type for Patients With Opioid Use Disorder"],"prefix":"10.1093","volume":"192","author":[{"given":"Kara E","family":"Rudolph","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas T","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iv\u00e1n","family":"D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean X","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Rotrosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward V","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,12,22]]},"reference":[{"issue":"2","key":"2023081316333348300_ref1","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1001\/jamapsychiatry.2018.3126","article-title":"Prevention and treatment of opioid misuse and addiction: a review","volume":"76","author":"Volkow","year":"2019","journal-title":"JAMA Psychiat."},{"key":"2023081316333348300_ref2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jsat.2018.06.001","article-title":"Developing an opioid use disorder treatment cascade: a review of quality measures","volume":"91","author":"Williams","year":"2018","journal-title":"J Subst Abuse Treat."},{"issue":"10118","key":"2023081316333348300_ref3","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet."},{"issue":"12","key":"2023081316333348300_ref4","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamapsychiatry.2017.3206","article-title":"Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: a randomized clinical noninferiority trial","volume":"74","author":"Tanum","year":"2017","journal-title":"JAMA Psychiat."},{"issue":"4","key":"2023081316333348300_ref5","doi-asserted-by":"crossref","first-page":"605","DOI":"10.15288\/jsad.2013.74.605","article-title":"Buprenorphine\/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from Starting Treatment with Agonist Replacement Therapies (START)","volume":"74","author":"Potter","year":"2013","journal-title":"J Stud Alcohol Drugs."},{"issue":"4","key":"2023081316333348300_ref6","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1046\/j.1360-0443.2003.00335.x","article-title":"Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients","volume":"98","author":"Mattick","year":"2003","journal-title":"Addiction."},{"issue":"2","key":"2023081316333348300_ref7","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst Rev."},{"issue":"4","key":"2023081316333348300_ref8","doi-asserted-by":"crossref","first-page":"e203711","DOI":"10.1001\/jamanetworkopen.2020.3711","article-title":"Association of racial\/ethnic segregation with treatment capacity for opioid use disorder in counties in the United States","volume":"3","author":"Goedel","year":"2020","journal-title":"JAMA Netw Open."},{"issue":"3","key":"2023081316333348300_ref9","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s11414-013-9341-3","article-title":"Variation in use of buprenorphine and methadone treatment by racial, ethnic, and income characteristics of residential social areas in New York city","volume":"40","author":"Hansen","year":"2013","journal-title":"J Behav Health Serv Res."},{"key":"2023081316333348300_ref10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.drugalcdep.2016.03.028","article-title":"Buprenorphine and methadone treatment for opioid dependence by income, ethnicity and race of neighborhoods in New York city","volume":"164","author":"Hansen","year":"2016","journal-title":"Drug Alcohol Depend."},{"issue":"1","key":"2023081316333348300_ref11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13722-021-00282-2","article-title":"Rural and urban differences in undersupply of buprenorphine provider availability in the United States, 2018","volume":"17","author":"Conway","year":"2022","journal-title":"Addict Sci Clin Pract."},{"issue":"10","key":"2023081316333348300_ref12","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1037\/ccp0000429","article-title":"Diverse diagnostic profiles associated with prescription opioid use disorder in a nationwide sample: one crisis, multiple needs","volume":"87","author":"Nadai","year":"2019","journal-title":"J Consult Clin Psychol."},{"key":"2023081316333348300_ref13","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jsat.2017.07.001","article-title":"Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population","volume":"85","author":"Morgan","year":"2018","journal-title":"J Subst Abuse Treat."},{"issue":"7","key":"2023081316333348300_ref14","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1176\/appi.ajp.2020.20060816","article-title":"Sublingual buprenorphine-naloxone compared with injection naltrexone for opioid use disorder: potential utility of patient characteristics in guiding choice of treatment","volume":"178","author":"Nunes","year":"2021","journal-title":"Am J Psychiatry."},{"key":"2023081316333348300_ref15","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.109031","article-title":"Optimizing opioid use disorder treatment with naltrexone or buprenorphine","volume":"228","author":"Rudolph","year":"2021","journal-title":"Drug Alcohol Depend."},{"issue":"2","key":"2023081316333348300_ref16","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/1467-9868.00389","article-title":"Optimal dynamic treatment regimes","volume":"65","author":"Murphy","year":"2003","journal-title":"J R Stat Soc Series B Stat Methodol."},{"issue":"3","key":"2023081316333348300_ref17","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/EDE.0000000000000991","article-title":"Selecting optimal subgroups for treatment using many covariates","volume":"30","author":"VanderWeele","year":"2019","journal-title":"Epidemiology."},{"issue":"1\u20132","key":"2023081316333348300_ref18","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.drugalcdep.2012.08.002","article-title":"Buprenorphine\/naloxone and methadone effects on laboratory indices of liver health: a randomized trial","volume":"128","author":"Saxon","year":"2013","journal-title":"Drug Alcohol Depend."},{"issue":"2","key":"2023081316333348300_ref19","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.cct.2010.01.003","article-title":"A multi-site, two-phase, Prescription Opioid Addiction Treatment Study (POATS): rationale, design, and methodology","volume":"31","author":"Weiss","year":"2010","journal-title":"Contemp Clin Trials."},{"key":"2023081316333348300_ref20","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/SAR.S16756","article-title":"The National Drug Abuse Treatment Clinical Trials Network: forging a partnership between research knowledge and community practice","volume":"2","author":"Tai","year":"2011","journal-title":"Subst Abuse Rehabil."},{"issue":"4","key":"2023081316333348300_ref21","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/add.13238","article-title":"Long-term outcomes after randomization to buprenorphine\/naloxone versus methadone in a multi-site trial","volume":"111","author":"Hser","year":"2016","journal-title":"Addiction."},{"issue":"1","key":"2023081316333348300_ref22","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/ADM.0000000000000274","article-title":"Distinctive trajectories of opioid use over an extended follow-up of patients in a multi-site trial on buprenorphine + naloxone and methadone","volume":"11","author":"Hser","year":"2017","journal-title":"J Addict Med."},{"issue":"12","key":"2023081316333348300_ref23","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1001\/archgenpsychiatry.2011.121","article-title":"Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial","volume":"68","author":"Weiss","year":"2011","journal-title":"Arch Gen Psychiatry."},{"key":"2023081316333348300_ref24","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.drugalcdep.2015.02.030","article-title":"Long-term outcomes from the national drug abuse treatment clinical trials network prescription opioid addiction treatment study","volume":"150","author":"Weiss","year":"2015","journal-title":"Drug Alcohol Depend."},{"issue":"3","key":"2023081316333348300_ref25","first-page":"1","article-title":"Mice: multivariate imputation by chained equations in R","volume":"45","author":"van Buuren","year":"2011","journal-title":"J Stat Softw."},{"key":"2023081316333348300_ref26","volume-title":"Twenty-fifth AAAI Conference on Artificial Intelligence","author":"Pearl"},{"issue":"1","key":"2023081316333348300_ref27","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/rssb.12299","article-title":"An omnibus non-parametric test of equality in distribution for unknown functions","volume":"81","author":"Luedtke","year":"2019","journal-title":"J R Stat Soc Series B Stat Methodology"},{"key":"2023081316333348300_ref28","volume-title":"Proceedings of the Second Seattle Symposium in Biostatistics","author":"Robins","year":"2004"},{"issue":"1","key":"2023081316333348300_ref29","doi-asserted-by":"crossref","first-page":"Article 4","DOI":"10.2202\/1557-4679.1052","article-title":"A doubly robust censoring unbiased transformation","volume":"3","author":"Rubin","year":"2007","journal-title":"Int J Biostat."},{"issue":"1","key":"2023081316333348300_ref30","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1515\/ijb-2015-0052","article-title":"Super-learning of an optimal dynamic treatment rule","volume":"12","author":"Luedtke","year":"2016","journal-title":"Int J Biostat."},{"key":"2023081316333348300_ref31","volume-title":"arXiv.","author":"Kennedy","year":"2020"},{"issue":"3","key":"2023081316333348300_ref32","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/biomet\/asy017","article-title":"Targeted learning ensembles for optimal individualized treatment rules with time-to-event outcomes","volume":"105","author":"D\u00edaz","year":"2018","journal-title":"Biometrika."},{"issue":"1","key":"2023081316333348300_ref33","article-title":"Super learner","volume":"6","author":"Laan","year":"2007","journal-title":"Stat Appl Genet Mol Biol."},{"issue":"1","key":"2023081316333348300_ref34","first-page":"1","article-title":"Multivariate adaptive regression splines","volume":"19","author":"Friedman","year":"1991","journal-title":"Ann Stat."},{"key":"2023081316333348300_ref35","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1145\/2939672.2939785","volume-title":"Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining","author":"Chen","year":"2016"},{"issue":"476","key":"2023081316333348300_ref36","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1198\/016214506000000735","article-title":"The adaptive lasso and its oracle properties","volume":"101","author":"Zou","year":"2006","journal-title":"J Am Stat Assoc."},{"issue":"2","key":"2023081316333348300_ref37","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1515\/ijb-2020-0073","article-title":"Doubly robust adaptive LASSO for effect modifier discovery","volume":"18","author":"Bahamyirou","year":"2022","journal-title":"Int J Biostat"},{"issue":"1","key":"2023081316333348300_ref38","doi-asserted-by":"crossref","first-page":"C1","DOI":"10.1111\/ectj.12097","article-title":"Double\/debiased machine learning for treatment and structural parameters: double\/debiased machine learning","volume":"21","author":"Chernozhukov","year":"2017","journal-title":"Econom J."},{"key":"2023081316333348300_ref39","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/978-1-4419-9782-1_27","volume-title":"Targeted Learning","author":"Zheng","year":"2011"},{"issue":"1","key":"2023081316333348300_ref40","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1515\/jci-2013-0022","article-title":"Targeted learning of the mean outcome under an optimal dynamic treatment rule","volume":"3","author":"Laan","year":"2015","journal-title":"J Casual Inference."},{"key":"2023081316333348300_ref41","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2020"},{"issue":"3","key":"2023081316333348300_ref42","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1177\/2167702618815466","article-title":"Sample size requirements for multivariate models to predict between-patient differences in best treatments of major depressive disorder","volume":"7","author":"Luedtke","year":"2019","journal-title":"Clin Psychol Sci."},{"issue":"1","key":"2023081316333348300_ref43","doi-asserted-by":"crossref","first-page":"35","DOI":"10.7326\/M18-3667","article-title":"The predictive approaches to treatment effect heterogeneity (path) statement","volume":"172","author":"Kent","year":"2020","journal-title":"Ann Intern Med."},{"issue":"9","key":"2023081316333348300_ref44","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jamapsychiatry.2019.0876","article-title":"Buprenorphine treatment divide by race\/ethnicity and payment","volume":"76","author":"Lagisetty","year":"2019","journal-title":"JAMA Psychiat."},{"issue":"1","key":"2023081316333348300_ref45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12954-021-00535-y","article-title":"\u201cIt\u2019s like \u2018liquid handcuffs\u201d: the effects of take-home dosing policies on Methadone Maintenance Treatment (MMT) patients\u2019 lives","volume":"18","author":"Frank","year":"2021","journal-title":"Harm Reduct J."},{"issue":"1","key":"2023081316333348300_ref46","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/0962280210386207","article-title":"Diagnosing and responding to violations in the positivity assumption","volume":"21","author":"Petersen","year":"2012","journal-title":"Stat Methods Med Res."},{"issue":"1","key":"2023081316333348300_ref47","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.2517-6161.1996.tb02080.x","article-title":"Regression shrinkage and selection via the lasso","volume":"58","author":"Tibshirani","year":"1996","journal-title":"J R Stat Soc B Methodol."},{"issue":"4","key":"2023081316333348300_ref48","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/add.12834","article-title":"A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales Australia","volume":"110","author":"Burns","year":"2015","journal-title":"Addiction."},{"issue":"1","key":"2023081316333348300_ref49","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/10550887.2016.1100960","article-title":"Retention in medication-assisted treatment for opiate dependence: a systematic review","volume":"35","author":"Timko","year":"2016","journal-title":"J Addict Dis."},{"issue":"3","key":"2023081316333348300_ref50","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study","volume":"169","author":"Larochelle","year":"2018","journal-title":"Ann Intern Med."},{"key":"2023081316333348300_ref51","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.drugalcdep.2019.02.031","article-title":"Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort","volume":"200","author":"Morgan","year":"2019","journal-title":"Drug Alcohol Depend."},{"issue":"2","key":"2023081316333348300_ref52","doi-asserted-by":"crossref","first-page":"e1920622","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative effectiveness of different treatment pathways for opioid use disorder","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Netw Open."},{"key":"2023081316333348300_ref53","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.cct.2016.09.006","article-title":"Ethical and clinical safety considerations in the design of an effectiveness trial: a comparison of buprenorphine versus naltrexone treatment for opioid dependence","volume":"51","author":"Nunes","year":"2016","journal-title":"Contemp Clin Trials."},{"issue":"1","key":"2023081316333348300_ref54","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/add.12333","article-title":"Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a multi-site trial","volume":"109","author":"Hser","year":"2014","journal-title":"Addiction."},{"issue":"3","key":"2023081316333348300_ref55","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s40264-020-01020-4","article-title":"Evaluation of opioid overdose reports in patients treated with extended-release naltrexone: Postmarketing data from 2006 to 2018","volume":"44","author":"Jain","year":"2021","journal-title":"Drug Saf."},{"issue":"2","key":"2023081316333348300_ref56","doi-asserted-by":"crossref","first-page":"e1921660","DOI":"10.1001\/jamanetworkopen.2019.21660","article-title":"Development and validation of a machine learning individualized treatment rule in first-episode schizophrenia","volume":"3","author":"Chi-Shin","year":"2020","journal-title":"JAMA Netw Open."}],"container-title":["American Journal of Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/aje\/advance-article-pdf\/doi\/10.1093\/aje\/kwac217\/49182164\/kwac217.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/aje\/article-pdf\/192\/5\/748\/51105663\/kwac217.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/aje\/article-pdf\/192\/5\/748\/51105663\/kwac217.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T21:30:30Z","timestamp":1728595830000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/aje\/article\/192\/5\/748\/6957041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,22]]},"references-count":56,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,12,22]]},"published-print":{"date-parts":[[2023,5,5]]}},"URL":"https:\/\/doi.org\/10.1093\/aje\/kwac217","relation":{},"ISSN":["0002-9262","1476-6256"],"issn-type":[{"value":"0002-9262","type":"print"},{"value":"1476-6256","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5]]},"published":{"date-parts":[[2022,12,22]]}}}